Head-to-head · free
AbbVie vs Moderna
ABBV vs MRNA — return on capital, cash generation, margins and balance sheet side by side.
ABBV
7 / 8
measures where ABBV leads
MRNA
1 / 8
measures where MRNA leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ABBV · FY2025 | MRNA · FY2025 |
|---|---|---|
| Revenue | $61.2B | $1.9B |
| Net income | $4.2B | (2.8B) |
| Revenue growth (yearly, multi-year) | 2.1% | -43.0% |
| Free cash flow | $17.8B | (2.1B) |
| Free cash flow margin | 29.1% | -106.2% |
| Net cash / (debt) | — | — |
| ROIC | 14.4% | — |
| Return on equity | — | -28.9% |
| Gross margin | 70.2% | 54.8% |
| Operating margin | 32.8% | -159.9% |
| Net debt / EBITDA | 2.68x | 0.70x |
Figures are as reported by each company; latest fiscal year shown.
Where AbbVie's cash went (FY2025)
- Capital spending
- $1.2B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Moderna's cash went (FY2025)
- Capital spending
- $192.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free